1. Generics Bulletin
  2. >>Products
  3. >>Generics

Micro Labs And Zydus Deal Quickly From Tofacitinib Action

Indian ANDA Sponsors Sued By Pfizer Over Xeljanz Earlier This Year

 
• By Dean Rudge

Hatch-Waxman cases filed by Pfizer against Micro Labs and Zydus Cadila over generic versions of Pfizer’s Xeljanz/Xeljanz XR will not move to trial, following settlement agreements covering two patents expiring in March 2023 and December 2025.

Handshake of businessmen
Details of the settlement agreements were not disclosed. • Source: Shutterstock

Indian abbreviated new drug application sponsors Micro Labs and Zydus Cadila have reached swiftly patent-litigation settlement agreements with Pfizer, after earlier being sued for their proposed generic versions of the originator’s JAK inhibitor Xeljanz (tofacitinib) in differing formulations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.